Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
| Autor: | Christoph Jakob Ackermann, Rebecca Tay, Fabio Gomes, Gustavo Trautman Stock, Raffaele Califano, Mohammed Dawod |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
business.industry medicine.medical_treatment medicine.disease respiratory tract diseases Targeted therapy Clinical trial 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Toxicity medicine Cancer research Initial treatment Pharmacology (medical) Non small cell business Lung cancer neoplasms Toxicity profile Tyrosine kinase |
| Zdroj: | OncoTargets and Therapy. 12:7857-7864 |
| ISSN: | 1178-6930 |
| DOI: | 10.2147/ott.s171665 |
| Popis: | Approximately 1-2% of unselected patients with Non-small Cell Lung Cancer (NSCLC) harbor RET rearrangements resulting in enhanced cell survival and proliferation. The initial treatment strategy for RET rearranged NSCLC has been multi-target tyrosine kinase inhibition. With overall response rates (ORR) of 16-53% and a median progression-free survival (PFS) of 4.5-7.3 months these outcomes are clearly inferior to the efficacy outcomes of selective tyrosine kinase inhibitors (TKI) in other oncogene-addicted NSCLC. Additionally, multi-kinase inhibition in RET-driven NSCLC patients showed concerning rates of high-grade toxicity, mainly induced by anti-VEGFR-kinase activity. Novel selective RET inhibitors like BLU-667, LOXO-292 and RXDX-105 have been recently investigated in early phase clinical trials showing promising efficacy with a manageable toxicity profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|